Mr. Thomas Smeenk reports

HEMOSTEMIX APPOINTS RENOWNED VASCULAR SURGEON AND PRINCIPAL INVESTIGATOR, DR. YORK HSIANG, AS BUSINESS CONSULTANT TO ADVANCE FIRST NATIONS-LED HEALTHCARE PARTNERSHIPS

Hemostemix Inc. has appointed Dr. York Hsiang as a business consultant.

"Since 2006, the first question I have asked every principal investigator I meet is simple: 'Doctor, does ACP-01 work?' Without exception, the answer has been an enthusiastic 'Yes.' When Dr. Hsiang answered that question, he added something I have never forgotten: ' ... in 30 years of medical practice I have not witnessed a therapy as effective as ACP-01,'" said Thomas Smeenk, president and chief executive officer, Hemostemix.

"For peripheral arterial disease patients, there are beneficial treatments to minimize pain and preserve function. However, for no option critical threatening limb ischemia (CTLI) patients, a timely amputation was the only procedure offered. ACP-01 is a dramatic game changer for suitable patients with no option CTLI. In 30 years of practice I have not seen a therapy as effective as ACP-01," said Dr. Hsiang.

Dr. Hsiang was a principal investigator of Hemostemix's phase II clinical trial of ACP-01, is a globally respected vascular surgeon and professor emeritus of surgery at the University of British Columbia (UBC) faculty of medicine. Over a career spanning more than three decades, Dr. Hsiang has been a leader in vascular surgery, endovascular innovation, clinical epidemiology and health-system governance in Canada.

He received his medical degree from the University of Otago, completed general and vascular surgery training at UBC, and pursued advanced training in health care evaluation and epidemiology through a master's degree and research fellowship at Harbor-UCLA. His leadership roles have included division head of vascular surgery at UBC, associate department head of surgery, and managing director of the physician staff association at Vancouver Hospital, where he also introduced and scaled hospital-based endovascular surgery programs.

Dr. Hsiang has published extensively on vascular disease outcomes, surgical innovation and health-system performance, and has collaborated in the development of novel vascular devices, including smart stent technologies for early restenosis detection. He has served as president of the Western Vascular Society, and holds fellowships and distinctions across leading vascular and surgical organizations internationally.

A deliberate step toward first nations-led health care sovereignty

Beyond his clinical credentials, Dr. Hsiang's appointment reflects a carefully developed strategy shaped over months of direct dialogue, listening and alignment with Canada's first nations.

Hemostemix is working collaboratively with first nations to ensure that any joint venture or clinical presence on First Nations Territories is grounded in:

• Respect for indigenous sovereignty and jurisdiction over health care, including governance, regulatory alignment and community consent;
• Long-term economic stewardship, with aligned incentives and intergenerational value creation;
• Capacity-building, training and local employment, including clinical, administrative, nursing and technical roles within the community;
• Physician-led, ethics-driven delivery of care for patients with no remaining conventional treatment options;
• A collaborative, long-term business plan to establish destination health care on first nations territories, positioning these communities as centres of healing based on clinical excellence, innovation and international patient care blended with traditional cultural healing methodologies.

Dr. Hsiang's decades of leadership, integrity and lived experience within Canada's health care institutions uniquely position him to translate these principles into operational clinics, governance structures and physician engagement models that align with first nations values and authorities.

Role and strategic mandate

As business consultant, Dr. Hsiang will advise Hemostemix on:

• Joint ventures with first nations governments to establish healthcare and treatment centres on sovereign territories;
• Clinical staffing models, physician engagement and standards of care for ACP-01 delivery;
• Strategic commercialization pathways in jurisdictions where Hemostemix has lawful access, including Canada, Florida under SB 1768 and The Bahamas' regenerative medicine framework;
• Ethical scale-up of ACP-01 for patients suffering from circulatory insufficiency who have exhausted conventional options.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer-reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 50 per cent in the CLTI patient population, UBC and University of Toronto reported to the 41st meeting of vascular surgeons: 0-per-cent mortality, cessation of pain, wound healing in 83 per cent of patients followed for up to 4.5 years, as a midpoint result.

We seek Safe Harbor.